MedCity is hosting its second NIHR Biomedical Research Centre (BRC) Showcase event on 15 March 2018 at Kings Place, London. Neelam Patel, MedCity COO, gives a brief teaser and explains why we have decided to focus on Cell and Gene Therapies.

The Golden Triangle of Cambridge, London and Oxford is home to world-class scientific research and ground-breaking medical innovations, which benefit not only the surrounding communities but have a global reach. Fundamental to the research success of the region are the NIHR BRCs; these organisations sit at the interface of academic institutions and leading NHS organisations, transforming scientific breakthroughs into life-saving treatments for patients.

Each BRC focuses on key research themes with cell and gene therapy, and the technologies associated with and evolving from them, underpinning a large portion of their biomedical research. Their world-first studies have led to significant breakthroughs, and in turn contribute to the UK’s international competitiveness as a major component of our knowledge economy.

The Golden Triangle is the leading centre of cell and gene therapy activity in Europe. In 2017, the UK had the highest ATMP clinical trial participation globally, with Cambridge, London and Oxford conducting over 80% of these trials.

The NIHR BRC Showcase event is a rare opportunity to meet all the region’s BRCs under one roof, to find out what makes them the key drivers of innovation in the translational cell and gene therapy environment in the UK and Europe.

Highlights will include…

• Exhibitions from 8 BRCs and the Cell and Gene Therapy Catapult, and a chance to book a 1:1 with them

• A panel on Perspectives in transitioning from the development of cell and gene therapies to commercialisation, including Professor Bobby Gaspar, Orchard Therapeutics; Professor Ludovic Vallier, Wellcome Sanger Institute; Dr Jim Faulkner, Senior Vice President, Autolus, and others.

Four Masterclasses:
Accelerating translation of the academic pipeline by the UCL Translational Research Office and UCL Business
• From Idea to Adoption – the NIHR Innovation Pathway by the NIHR
• The importance of early planning for ATMP reimbursement by the Cell and Gene Therapy Catapult
• Oncolytic viruses as a new gene therapy- an example of taking a novel approach from the laboratory into the clinic by Royal Marsden NHS Hospital

Read the full agenda and sign up here: